[关键词]
[摘要]
目的 了解郑州市第六人民医院应用伏立康唑所致药品不良反应(ADR)的特点、一般规律及预后,为临床安全合理使用伏立康唑提供参考。方法 对2018年1~12月使用伏立康唑的162例病例进行回顾性分析,共计54例患者出现不良反应,按是否合并艾滋病(AIDS)、患者性别、年龄、给药方式、ADR发生时间、累及的器官或系统、转归等进行统计分析。结果 54例ADR中,AIDS患者42例,非AIDS患者12例;男性39例,女性15例;41~70岁的有39例。2~5 d内发生ADR的有27例,占50%;不良反应以神经系统损害最多,其余可涉及肝胆系统、皮肤及其附件、视觉系统等。1例肾损害患者留有后遗症,其余经过停药或对症处理后均好转。结论 AIDS患者使用伏立康唑不良反应发生率显著高于非AIDS患者,临床在合理用药的同时,对AIDS患者尤其应加强监测。
[Key word]
[Abstract]
Objective To analyze the characteristics, general rules, and prognosis of adverse reactions induced by voriconazole in the Sixth People's Hospital of Zhengzhou in 2018, and to provide reference for rational use of voriconazole. Methods A retrospective analysis was conducted on 162 patients who used voriconazole from January to December 2018, and a total of 54 patients had ADR, and the 54 cases were analyzed in terms of whether combined AIDS, sex, age, mode of administration, time of ADR, organs or systems involved, outcome, etc. Results In 54 cases of ADR, there were 42 cases of patients with AIDS, and 12 cases without AIDS. There were 39 cases of male patients and 15 cases of female patients. Most of ADR occurred in patients of 41-70 years old. There were 27 cases of ADR occurred within 2-5 d, accounting for 50%. Mental disorder was the major clinical manifestation, followed by liver damage, skin lesions, and visual impairment, etc. After withdrawal of voriconazole and symptomatic treatment, most of the symptoms disappeared, except one patient with renal injury had sequel. Conclusion The incidence of voriconazole in AIDS patients is higher than others, so the monitoring of AIDS patients should be strengthened on basis of rational use.
[中图分类号]
R969.3
[基金项目]
“十三五”艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2017ZX10202101-001-010)